COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events

Inclusion Criteria:

1. Patients undergoing PCI, aged 30-80 years with any clinical presentation

2. Angiographic criteria: presence of ≥ 2 de novo target lesions* located in 2different native coronary arteries feasible for treatment with PCI (operator / Heartteam decision)

Angiographic criteria target lesion* (all criteria I-IV should be applicable):

I. DS ≥ 50% on visual estimation II. de novo lesion located in native (non-grafted) vessel III. lesion reference diameter of ≥ 2.0 mm IV. Thrombolysis In Myocardial Infarction (TIMI) 3 flow in all vessels (with exclusion of culprit lesions if MI at presentation)

*Target lesions are either culprit MI lesions or lesions where FFR will be performed. Patients are eligible if they have ≥ 2 target lesions or one culprit and ≥ 1 target lesion.

Exclusion Criteria:

1. Patients with MVD requiring coronary artery bypass grafting (CABG) treatment (operator / local heart team decision)

2. Lesion located in a grafted segment or in a vein graft

3. In-stent restenosis lesions

4. Left main trifurcation

5. Left main lesion stand-alone (without other lesions)

6. Patients with severe tortuous lesions (where FFR and OCT is judged impossible ordangerous)

7. Chronic total occlusion

8. Spontaneous coronary dissection

9. Patients with severe valvular heart disease likely to require cardiac surgery withinthe next 2 years

10. Patients with left ventricle (LV) function less than 30%

11. Renal insufficiency (Glomerular Filtration Rate (GFR) < 29 ml/min/1.73m2; KidneyDisease Outcomes Quality Initiative (KDOQI) stage 4 and 5)

12. Life expectancy less than 3 years